|
1
|
Vernon G, Baranova A and Younossi ZM:
Systematic review: The epidemiology and natural history of
non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
in adults. Aliment Pharmacol Ther. 34:274–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chalasani N, Younossi Z, Lavine JE, Diehl
AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and
management of nonalcoholic fatty liver disease: Practice guideline
by the American Association for the Study of Liver Diseases,
American College of Gastroenterology, and the American
Gastroenterological Association. Hepatology. 55:2005–2023. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chachay VS, Macdonald GA, Martin JH,
Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K,
Taylor PJ, Ferguson M, et al: Resveratrol does not benefit patients
with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol.
12:2092–2103.e1-e6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Charlton MR, Burns JM, Pedersen RA, Watt
KD, Heimbach JK and Dierkhising RA: Frequency and outcomes of liver
transplantation for nonalcoholic steatohepatitis in the United
States. Gastroenterology. 141:1249–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bonora E and Targher G: Increased risk of
cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev
Gastroenterol Hepatol. 9:372–381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Angulo P: Nonalcoholic fatty liver
disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fracanzani AL, Burdick L, Raselli S,
Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano
A and Fargion S: Carotid artery intima-media thickness in
nonalcoholic fatty liver disease. Am J Med. 121:72–78. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frémont L: Biological effects of
resveratrol. Life Sci. 66:663–673. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kopec KL and Burns D: Nonalcoholic fatty
liver disease: A review of the spectrum of disease, diagnosis, and
therapy. Nutr Clin Pract. 26:565–576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lagouge M, Argmann C, Gerhart-Hines Z,
Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P,
Elliott P, et al: Resveratrol improves mitochondrial function and
protects against metabolic disease by activating SIRT1 and
PGC-1alpha. Cell. 127:1109–1122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gómez-Zorita S, Fernández-Quintela A,
Macarulla M, Aguirre L, Hijona E, Bujanda L, Milagro F, Martínez JA
and Portillo MP: Resveratrol attenuates steatosis in obese Zucker
rats by decreasing fatty acid availability and reducing oxidative
stress. Br J Nutr. 107:202–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng MD, Fan JG, Lu LG, Li YM, Chen CW,
Wang BY and Mao YM; Chinese National Consensus Workshop on
Nonalcoholic Fatty Liver Disease, : Guidelines for the diagnosis
and treatment of nonalcoholic fatty liver diseases. J Dig Dis.
9:108–112. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia MF, Yan HM, He WY, Li XM, Li CL, Yao
XZ, Li RK, Zeng MS and Gao X: Standaridized ultrasound
hepatic/renal ratio and hepatic attenuation rate to quantify liver
fat content: An improvement method. Obesity (Silver Spring).
20:444–452. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
von Volkmann HL, Havre RF, Løberg EM,
Haaland T, Immervoll H, Haukeland JW, Hausken T and Gilja OH:
Quantitative measurement of ultrasound attenuation and hepato-renal
index in non-alcoholic fatty liver disease. Med Ultrason. 15:16–22.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramadori G, Moriconi F, Malik I and Dudas
J: Physiology and pathophysiology of liver inflammation damage and
repair. J Physiol Pharmacol. 59 (Suppl 1):S107–S117. 2008.
|
|
16
|
Jaeschke H, Gores GJ, Cederbaum AI, Hinson
JA, Pessayre D and Lemasters JJ: Mechanisms of hepatotoxicity.
Toxicol Sci. 65:166–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tietz Textbook of clinical chemistry, .
Burtis CA, Ashwood ER and Saunders WB; Company, : Philadelphia:
1994
|
|
18
|
Clark JM, Brancati FL and Diehl AM: The
prevalence and etiology of elevated aminotransferase levels in the
United States. Am J Gastroenterol. 98:960–967. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bedogni G, Miglioli L, Masutti F,
Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk
factors for nonalcoholic fatty liver disease: The Dionysos
nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adams LA, Lymp JF, St Sauver J, Sanderson
SO, Lindor KD, Feldstein A and Angulo P: The natural history of
nonalcoholic fatty liver disease: A population-based cohort study.
Gastroenterology. 129:113–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paschos P and Paletas K: Nonalcoholic
fatty liver disease and metabolic syndrome. Hippokratia. 13:9–19.
2009.PubMed/NCBI
|
|
22
|
Duvnjak M, Lerotić I, Barsić N, Tomasić V,
Virović Jukić L and Velagić V: Pathogenesis and management issues
for non-alcoholic fatty liver disease. World J Gastroenterol.
13:4539–4550. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alberti KG, Zimmet P and Shaw J; IDF
Epidemiology Task Force Consensus Group, : The metabolic syndrome-a
new worldwide definition. Lancet. 366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahmed MH and Byrne CD: Modulation of
sterol regulatory element binding proteins (SREBPs) as potential
treatments for non-alcoholic fatty liver disease (NAFLD). Drug
Discov Today. 12:740–747. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baur JA, Pearson KJ, Price NL, Jamieson
HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K,
et al: Resveratrol improves health and survival of mice on a
high-calorie diet. Nature. 444:337–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Price NL, Gomes AP, Ling AJ, Duarte FV,
Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro
JS, et al: SIRT1 is required for AMPK activation and the beneficial
effects of resveratrol on mitochondrial function. Cell Metab.
15:675–690. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang YM, Han CY, Kim YJ and Kim SG:
AMPK-associated signaling to bridge the gap between fuel metabolism
and hepatocyte viability. World J Gastroenterol. 16:3731–3742.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Xu S, Mihaylova MM, Zheng B, Hou X,
Jiang B, Park O, Luo Z, Lefai E, Shyy JY, et al: AMPK
phosphorylates and inhibits SREBP activity to attenuate hepatic
steatosis and atherosclerosis in diet-induced insulin-resistant
mice. Cell Metab. 13:376–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alberdi G, Rodríguez VM, Macarulla MT,
Miranda J, Churruca I and Portillo MP: Hepatic lipid metabolic
pathways modified by resveratrol in rats fed an obesogenic diet.
Nutrition. 29:562–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Colak Y, Ozturk O, Senates E, Tuncer I,
Yorulmaz E, Adali G, Doganay L and Enc FY: SIRT1 as a potential
therapeutic target for treatment of nonalcoholic fatty liver
disease. Med Sci Monit. 17:HY5–HY9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Purushotham A, Schug TT, Xu Q, Surapureddi
S, Guo X and Li X: Hepatocyte-specific deletion of SIRT1 alters
fatty acid metabolism and results in hepatic steatosis and
inflammation. Cell Metab. 9:327–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L, Hai J, Li Z, Zhang Y, Peng H, Li K
and Weng X: Resveratrol modulates autophagy and NF-κB activity in a
murine model for treating non-alcoholic fatty liver disease. Food
Chem Toxicol. 263:166–173. 2014. View Article : Google Scholar
|
|
33
|
Castro RE, Ferreira DM, Afonso MB,
Borralho PM, Machado MV, Cortez-Pinto H and Rodrigues CM:
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat
liver and activated by disease severity in human non-alcoholic
fatty liver disease. J Hepatol. 58:119–125. 2013. View Article : Google Scholar : PubMed/NCBI
|
